XORTX Therapeutics (XRTX) Q2 2024 earnings summary

Executive summary

• Focused on developing therapies for progressive kidney disease, with ongoing clinical and regulatory programs targeting orphan and prevalent indications.

• Operations are based in Canada, with shares listed on TSXV and Nasdaq.

Financial highlights

• Net loss for six months ended June 30, 2024 was $2.85M, an improvement from $3.52M loss in the same period last year.

• Net income of $170K for Q2 2024, compared to a loss of $1.69M in Q2 2023, driven by a $1.65M fair value gain on derivative warrant liability.

• Cash at June 30, 2024 was $3.08M, down from $3.45M at December 31, 2023.

• Total assets decreased to $4.80M from $5.47M at year-end 2023.

• Shareholders' equity declined to $2.70M from $4.64M at December 31, 2023.

Outlook and guidance

• Management plans to raise additional capital to fund research, development, and clinical studies.

• Future product sales are contingent on regulatory approvals; delays in financing may postpone research activities.